China's push to use artificial intelligence in designing new drugs is gaining momentum, with deals in the sector swelling even as the United States steps up scrutiny of the field, according to the South China Morning Post.
The report frames a striking contrast: rather than cooling off under pressure from Washington, dealmaking around AI-driven drug discovery in China appears to be accelerating. The trend sits at the intersection of two forces that have defined recent US-China tension — rapid advances in artificial intelligence, and mounting concern in Washington about the flow of technology and investment between the two countries.
AI-assisted drug design uses machine-learning models to speed up parts of pharmaceutical research that traditionally take years, such as identifying promising molecules and predicting how they might behave. It has become one of the most closely watched applications of AI, drawing interest from both biotech firms and technology companies.
The South China Morning Post reports that this activity is growing in China against a backdrop of rising American scrutiny. The item does not detail the specific companies involved, the size of the deals, or the exact nature of the US measures.
Why it matters: The pace of China's AI drug-design dealmaking suggests that tighter US oversight has not slowed one of the most strategically significant uses of artificial intelligence, underscoring how AI and biotechnology are becoming central to the broader technology rivalry between the world's two largest economies.